"We have the potential to reinvent Lundbeck"

If Lundbeck succeeds in developing an Alzheimer's drug, it can potentially generate a revenue comparable to the whole company's current total revenue. This is according to EVP Bjørn Grønning.

Photo: Joachim Rode

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles